Emirates Drug Establishment Approves Lipfendra for Elevated LDL Cholesterol Treatment

DUBAI — The Emirates Drug Establishment (EDE) has officially approved Lipfendra, a once-daily oral medication designed to treat adults with elevated low-density lipoprotein (LDL) cholesterol, including specific inherited conditions. When used in conjunction with a balanced diet and regular physical activity, Lipfendra helps lower “bad” cholesterol to reduce cardiovascular disease risks. With this swift authorization, the UAE has become only the second country worldwide to approve the treatment, highlighting the nation’s efficient regulatory framework and dedication to providing rapid patient access to innovative medical breakthroughs.